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Letter to Editor
Age-related loss of skeletal muscle mass and quality
(“Sarcopenia”) represents a relevant aspect of the senescent
phenotype and a major cause of “frailty”, disability and loss of
independence of the elderly [1]. Although extremely common,
this phenomenon is poorly understood in its causes and
mechanisms, which is also reflected by the lack of specific
therapeutic approaches except for nutrition and physical
activity, often leading to only limited benefit.
The Insulin-IGF (Insulin-like Growth Factor) signaling pathway
(IIS) is pivotal to muscle growth and maintenance, mainly
through the Akt-FoxO (Forkhead box O), and Akt-mTOR
(mammalian Target of Rapamycin) sub-branches, that,
respectively, prevent muscle atrophy and promote protein build-
up [1]. Evidence exist that IGF content and IIS is reduced in the
senescent muscle, because of a combination of reduced fiber
volume (and glucose disposal capacity), mitochondrial
dysfunction and oxidative stress [2]. Accordingly, sarcopenia has
been often found to associate with systemic insulin resistance
[3]. However, establishing a causative link between reduced
response to IIS and age-related muscle wasting has proven
difficult for a number of reasons. First, sarcopenia often
develops in combination with obesity (“sarcopenic obesity”), a
condition that in turn represents a major cause of insulin
resistance in the elderly [4]. Excess adiposity may impair muscle
response to insulin by excess release of saturated fatty acids
(SFA), or through the establishment of a generalized, subclinical
low-grade inflammation (metainflammation) [5], that is known
to desensitize insulin responses at a post-receptorial level. Either
way, insulin resistance in sarcopenic obesity may not necessarily
account for muscle loss, but simply represent a comorbidity
induced by excess adiposity or the associated inflammation.
Additionally, muscle represents the major site of glucose
disposal in the healthy individual [6], implying that a relative
resistance to insulin may well represent a consequence, rather
than a cause, of generalized muscle atrophy. Or at least that a
mutual relationship between the two phenomena could be
envisaged. Importantly, however, studies performed on
transgenic animals overexpressing the master inflammation
regulator NF-kB in muscle have demonstrated that significant
loss of muscle mass can occur without the establishment of
systemic glucose intolerance [7]. Instead, primary loss of insulin
response can promote proinflammatory signaling in the muscle
[8].
Notwithstanding the above confounding evidence, we stand
for the idea that muscle resistance to anabolic IIS signaling
represents a major driver of age-related or (“primary”)
sarcopenia. It is conceivable that loss of mitochondrial mass and
oxidative capacity (and the resulting build-up of reactive oxygen
species) occurs in the senescent muscle as an early event
disrupting of insulin response [9], even in the presence of a
preserved muscle mass. Given the role of muscle in glucose
disposal, this could result in altered glucostasis, hyperinsulinism
and possibly even increased adiposity. In alternative, muscle
may develop a “selective insulin resistance”, whereby mTOR-
dependent protein anabolism, but not glucose internalization
and oxidation in the muscle are disrupted [10]. As a further
possibility, glucose disposal capacity of liver and adipose may
compensate for muscle loss of insulin responsiveness, thus
maintaining overall glucose homeostasis within normal limits in
sarcopenic individuals. Of note, in the latter two cases, clinical
glucose intolerance may not be detected in sarcopenic
individuals.
In recent years basic and translational research have
established multifaceted connections between nutrient signaling
through the IIS pathway and the ageing process [11]. While in
model organisms attenuation of systemic insulin action is
accompanied by extended lifespan, in mammals tissue specific
senescence, as in Alzheimer-like neurodegeneration or
endothelial dysfunction, often reflect a defect in response to
insulin signaling [12]. Importantly, such defect may involve not
only mature cell types, but also stem cells deputed to tissue
regeneration and maintenance, and may be due to both cell-
intrinsic as well as environmental, blood-born factors [13].
We suggest that age-related sarcopenia may be the result of a
tissue-specific impairment of insulin signaling, a form of
“muscle-specific diabetes”. Systemic evaluation and possibly
validation of this hypothesis may entail important consequences
for the prevention and therapy of sarcopenia, from the
development of diagnostic procedures/biomarkers aimed at
specifically addressing muscle response to insulin, to the
evaluation of insulin sensitizing drugs (Metformin,
Thiazolidinediones) for muscle mass maintenance in the elderly
even in the absence of overt diabetes.
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